GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCell Pharma AB (OSTO:NXTCL) » Definitions » Investments And Advances

NextCell Pharma AB (OSTO:NXTCL) Investments And Advances : kr0.00 Mil (As of Feb. 2024)


View and export this data going back to 2017. Start your Free Trial

What is NextCell Pharma AB Investments And Advances?

NextCell Pharma AB's Investments And Advances for the quarter that ended in Feb. 2024 was kr0.00 Mil.


NextCell Pharma AB Investments And Advances Historical Data

The historical data trend for NextCell Pharma AB's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCell Pharma AB Investments And Advances Chart

NextCell Pharma AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only - - - - -

NextCell Pharma AB Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NextCell Pharma AB Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


NextCell Pharma AB (OSTO:NXTCL) Business Description

Traded in Other Exchanges
Address
Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.

NextCell Pharma AB (OSTO:NXTCL) Headlines

No Headlines